Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the stock. HC Wainwright reiterated a “neutral” rating and issued a $2.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS opened at $0.55 on Monday. Marinus Pharmaceuticals has a 52-week low of $0.22 and a 52-week high of $9.69. The company has a 50-day simple moving average of $0.54 and a 200 day simple moving average of $0.79. The company has a market capitalization of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03.

Institutional Trading of Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in Marinus Pharmaceuticals during the 4th quarter worth about $36,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Marinus Pharmaceuticals during the fourth quarter valued at about $54,000. World Investment Advisors LLC acquired a new stake in Marinus Pharmaceuticals in the third quarter valued at approximately $104,000. Deltec Asset Management LLC bought a new stake in Marinus Pharmaceuticals during the 4th quarter valued at $107,000. Finally, XTX Topco Ltd raised its holdings in Marinus Pharmaceuticals by 1,564.7% during the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 206,614 shares during the last quarter. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.